0001415889-22-008896.txt : 20220819
0001415889-22-008896.hdr.sgml : 20220819
20220819160650
ACCESSION NUMBER: 0001415889-22-008896
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220817
FILED AS OF DATE: 20220819
DATE AS OF CHANGE: 20220819
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cavanaugh Sarah
CENTRAL INDEX KEY: 0001709113
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 221180841
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
form4-08192022_010836.xml
X0306
4
2022-08-17
0000744218
Celldex Therapeutics, Inc.
CLDX
0001709113
Cavanaugh Sarah
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
false
true
false
false
SVP OF CORP AFFAIRS & ADMIN.
Common Stock
2022-08-17
4
M
0
31312
2.78
A
32596
D
Common Stock
2022-08-17
4
S
0
31312
36.7342
D
1284
D
Common Stock
2022-08-18
4
M
0
1355
9.0165
A
2639
D
Common Stock
2022-08-18
4
S
0
1355
36.3757
D
1284
D
Incentive Stock Option
2.78
2022-08-17
4
M
0
31312
0
D
2029-06-19
Common Stock
31312
10750
D
Incentive Stock Option
9.0165
2022-08-18
4
M
0
1355
0
D
2028-06-13
Common Stock
1355
10103
D
Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
As of June 13, 2022, the option is fully vested.
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
2022-08-19